The company achieved strong business execution in 2025 with continued momentum across programs, and 2026 has started with derisking events for two key programs (ITK and ATI-052). Aclaris maintains a strong cash position with several meaningful catalysts expected across its biologics and ITK pipeline this year.
Cyborg Score Rationale
Aclaris demonstrates solid execution with multiple clinical catalysts in 2026 and positive Phase 1a data derisking early programs. However, the company is pre-revenue clinical stage with significant development risk ahead, though cash runway extends into H2 2028 providing adequate runway for near-term milestones.
Top Insights
ATI-052 Phase 1a trial demonstrated strong safety and tolerability profiles with robust target engagement validating compound potency at low doses.
Lead ITK inhibitor ATI-9494 has shown potent Th1/Th2 blockade and prolonged half-life, with IND application expected in H2 2026.
ATI-2138 demonstrated rapid and sustained hair regrowth in murine models of severe alopecia areata, validating best-in-class potential.
Phase 1b POC trials underway for ATI-052 with top-line results expected H2 2026, plus Phase 2 results anticipated for anti-TSLP antibody bosakitug.
Named Competitors
Ritlecitinib — JAK inhibitor for alopecia areata
Dupilumab — Anti-IL-4R monoclonal antibody for atopic dermatitis and asthma
Tezepelumab — Anti-TSLP monoclonal antibody for asthma
Recent Developments
(Feb 2026) Positive Phase 1a interim results for ATI-052 bispecific antibody showing strong safety and target engagement
(Feb 2026) Initiated two Phase 1b proof-of-concept trials for ATI-052 in atopic dermatitis and asthma
(Feb 2026) Preclinical data showing ATI-2138 rapid hair regrowth in severe alopecia universalis model
(Dec 2025) Added to NASDAQ Biotechnology Index (NBI)
Open the full interactive Aclaris Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.